The Hair Loss Encyclopedia

Search

for
Search:

GlossaryGefitinib

inhibits EGFR to treat certain non-small cell lung cancers

Gefitinib, also known as Iressa, is a medication used to treat certain types of non-small cell lung cancer. It works by inhibiting the epidermal growth factor receptor (EGFR), which is involved in the growth and spread of cancer cells. By blocking this receptor, gefitinib can help slow down or stop the progression of the cancer.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 156 results

research Gefitinib: An Adverse Effects Profile

44 citations , April 2006 in “Expert opinion on drug safety”

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

research Erosive Pustular Dermatosis of the Scalp-Like Eruption Due to Gefitinib: Case Report and Review of Alopecia Associated with EGFR Inhibitors

36 citations , January 2012 in “Dermatology”

Stopping gefitinib improved scalp condition in a woman with lung cancer.

research Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib

6 citations , May 2013 in “Journal of Clinical Oncology”

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Erosive Pustular Dermatosis of the Scalp Induced by Gefitinib: Case and Review of the Literature

research Erosive Pustular Dermatosis of the Scalp Induced by Gefitinib: Case and Review of the Literature

5 citations , January 2021 in “Dermatology Online Journal”

An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.

research The Dark Side Of Gefitinib: Reflectance Confocal Microscopy Applied To Hair Hyperpigmentation

4 citations , October 2019 in “Skin Appendage Disorders”

Gefitinib can cause hair and eyebrow darkening.

View more "gefitinib" in research →

Community Join

0 / 0 results

— no results